Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Advance AKIR001 in Solid Tumors
Uppsala and Garching/Munich, August 20, 2026 Akiram Therapeutics has entered into a Lutetium-177 (Lu-177) supply agreement with ITM Isotope...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Uppsala and Garching/Munich, August 20, 2026 Akiram Therapeutics has entered into a Lutetium-177 (Lu-177) supply agreement with ITM Isotope...
ALBUQUERQUE, N.M., May 5, 2026 Eden Radioisotopes, LLC has filed a Construction Permit Application with the U.S. Nuclear Regulatory...
